Importance of target-mediated drug disposition for small molecules

•Target-mediated drug disposition for small molecules is not addressed systematically.•TMDD has a major influence on drug distribution and clearance.•TMDD results in unpredictable and non-linear pharmacokinetics.•TMDD confounds human microdosing approaches. Target concentration is typically not cons...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug discovery today 2018-12, Vol.23 (12), p.2023-2030
Hauptverfasser: Smith, Dennis A., van Waterschoot, Robert A.B., Parrott, Neil J., Olivares-Morales, Andrés, Lavé, Thierry, Rowland, Malcolm
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2030
container_issue 12
container_start_page 2023
container_title Drug discovery today
container_volume 23
creator Smith, Dennis A.
van Waterschoot, Robert A.B.
Parrott, Neil J.
Olivares-Morales, Andrés
Lavé, Thierry
Rowland, Malcolm
description •Target-mediated drug disposition for small molecules is not addressed systematically.•TMDD has a major influence on drug distribution and clearance.•TMDD results in unpredictable and non-linear pharmacokinetics.•TMDD confounds human microdosing approaches. Target concentration is typically not considered in drug discovery. However, if targets are expressed at relatively high concentrations and compounds have high affinity, such that most of the drug is bound to its target, in vitro screens can give unreliable information on compound affinity. In vivo, a similar situation will generate pharmacokinetic (PK) profiles that deviate greatly from those normally expected, owing to target binding affecting drug distribution and clearance. Such target-mediated drug disposition (TMDD) effects on small molecules have received little attention and might only become apparent during clinical trials, with the potential for data misinterpretation. TMDD also confounds human microdosing approaches by providing therapeutically unrepresentative PK profiles. Being aware of these phenomena will improve the likelihood of successful drug discovery and development.
doi_str_mv 10.1016/j.drudis.2018.06.010
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2058499901</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1359644618300837</els_id><sourcerecordid>2058499901</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-a18cbdadbee7461cbdcdc79189e4c503c8b1c5197235e7ca3db0790fa28d8fbc3</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhi0EoqXwDxDKyJJgO3FiL0hQ8VGpEgvMlmNfKldJXWwHiX-PqxRGprvhfe_RPQhdE1wQTOq7bWH8aGwoKCa8wHWBCT5Bc8IbnjNe0tO0l0zkdVXVM3QRwhZjQgWrz9GMCkE5Z3iOHlfD3vmodhoy12VR-Q3EfABjVQSTJcQmS5C9CzZat8s657MwqL7PBteDHnsIl-isU32Aq-NcoI_np_fla75-e1ktH9a5Lmsac0W4bo0yLUBT1STt2uhGEC6g0gyXmrdEMyIaWjJotCpNixuBO0W54V2rywW6ne7uvfscIUQ52KCh79UO3BgkxYxXQghMUrSaotq7EDx0cu_toPy3JFge7MmtnOzJgz2Ja5nspdrNkTC2ScFf6VdXCtxPAUh_flnwMmgLyZ2xHnSUxtn_CT_X_YQJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2058499901</pqid></control><display><type>article</type><title>Importance of target-mediated drug disposition for small molecules</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Smith, Dennis A. ; van Waterschoot, Robert A.B. ; Parrott, Neil J. ; Olivares-Morales, Andrés ; Lavé, Thierry ; Rowland, Malcolm</creator><creatorcontrib>Smith, Dennis A. ; van Waterschoot, Robert A.B. ; Parrott, Neil J. ; Olivares-Morales, Andrés ; Lavé, Thierry ; Rowland, Malcolm</creatorcontrib><description>•Target-mediated drug disposition for small molecules is not addressed systematically.•TMDD has a major influence on drug distribution and clearance.•TMDD results in unpredictable and non-linear pharmacokinetics.•TMDD confounds human microdosing approaches. Target concentration is typically not considered in drug discovery. However, if targets are expressed at relatively high concentrations and compounds have high affinity, such that most of the drug is bound to its target, in vitro screens can give unreliable information on compound affinity. In vivo, a similar situation will generate pharmacokinetic (PK) profiles that deviate greatly from those normally expected, owing to target binding affecting drug distribution and clearance. Such target-mediated drug disposition (TMDD) effects on small molecules have received little attention and might only become apparent during clinical trials, with the potential for data misinterpretation. TMDD also confounds human microdosing approaches by providing therapeutically unrepresentative PK profiles. Being aware of these phenomena will improve the likelihood of successful drug discovery and development.</description><identifier>ISSN: 1359-6446</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/j.drudis.2018.06.010</identifier><identifier>PMID: 29928850</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Clinical Trials as Topic ; Drug Delivery Systems - methods ; Humans ; Small Molecule Libraries - pharmacokinetics ; Tissue Distribution - physiology</subject><ispartof>Drug discovery today, 2018-12, Vol.23 (12), p.2023-2030</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-a18cbdadbee7461cbdcdc79189e4c503c8b1c5197235e7ca3db0790fa28d8fbc3</citedby><cites>FETCH-LOGICAL-c362t-a18cbdadbee7461cbdcdc79189e4c503c8b1c5197235e7ca3db0790fa28d8fbc3</cites><orcidid>0000-0001-9959-0810</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1359644618300837$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29928850$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smith, Dennis A.</creatorcontrib><creatorcontrib>van Waterschoot, Robert A.B.</creatorcontrib><creatorcontrib>Parrott, Neil J.</creatorcontrib><creatorcontrib>Olivares-Morales, Andrés</creatorcontrib><creatorcontrib>Lavé, Thierry</creatorcontrib><creatorcontrib>Rowland, Malcolm</creatorcontrib><title>Importance of target-mediated drug disposition for small molecules</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>•Target-mediated drug disposition for small molecules is not addressed systematically.•TMDD has a major influence on drug distribution and clearance.•TMDD results in unpredictable and non-linear pharmacokinetics.•TMDD confounds human microdosing approaches. Target concentration is typically not considered in drug discovery. However, if targets are expressed at relatively high concentrations and compounds have high affinity, such that most of the drug is bound to its target, in vitro screens can give unreliable information on compound affinity. In vivo, a similar situation will generate pharmacokinetic (PK) profiles that deviate greatly from those normally expected, owing to target binding affecting drug distribution and clearance. Such target-mediated drug disposition (TMDD) effects on small molecules have received little attention and might only become apparent during clinical trials, with the potential for data misinterpretation. TMDD also confounds human microdosing approaches by providing therapeutically unrepresentative PK profiles. Being aware of these phenomena will improve the likelihood of successful drug discovery and development.</description><subject>Animals</subject><subject>Clinical Trials as Topic</subject><subject>Drug Delivery Systems - methods</subject><subject>Humans</subject><subject>Small Molecule Libraries - pharmacokinetics</subject><subject>Tissue Distribution - physiology</subject><issn>1359-6446</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD1PwzAQhi0EoqXwDxDKyJJgO3FiL0hQ8VGpEgvMlmNfKldJXWwHiX-PqxRGprvhfe_RPQhdE1wQTOq7bWH8aGwoKCa8wHWBCT5Bc8IbnjNe0tO0l0zkdVXVM3QRwhZjQgWrz9GMCkE5Z3iOHlfD3vmodhoy12VR-Q3EfABjVQSTJcQmS5C9CzZat8s657MwqL7PBteDHnsIl-isU32Aq-NcoI_np_fla75-e1ktH9a5Lmsac0W4bo0yLUBT1STt2uhGEC6g0gyXmrdEMyIaWjJotCpNixuBO0W54V2rywW6ne7uvfscIUQ52KCh79UO3BgkxYxXQghMUrSaotq7EDx0cu_toPy3JFge7MmtnOzJgz2Ja5nspdrNkTC2ScFf6VdXCtxPAUh_flnwMmgLyZ2xHnSUxtn_CT_X_YQJ</recordid><startdate>201812</startdate><enddate>201812</enddate><creator>Smith, Dennis A.</creator><creator>van Waterschoot, Robert A.B.</creator><creator>Parrott, Neil J.</creator><creator>Olivares-Morales, Andrés</creator><creator>Lavé, Thierry</creator><creator>Rowland, Malcolm</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9959-0810</orcidid></search><sort><creationdate>201812</creationdate><title>Importance of target-mediated drug disposition for small molecules</title><author>Smith, Dennis A. ; van Waterschoot, Robert A.B. ; Parrott, Neil J. ; Olivares-Morales, Andrés ; Lavé, Thierry ; Rowland, Malcolm</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-a18cbdadbee7461cbdcdc79189e4c503c8b1c5197235e7ca3db0790fa28d8fbc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Clinical Trials as Topic</topic><topic>Drug Delivery Systems - methods</topic><topic>Humans</topic><topic>Small Molecule Libraries - pharmacokinetics</topic><topic>Tissue Distribution - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smith, Dennis A.</creatorcontrib><creatorcontrib>van Waterschoot, Robert A.B.</creatorcontrib><creatorcontrib>Parrott, Neil J.</creatorcontrib><creatorcontrib>Olivares-Morales, Andrés</creatorcontrib><creatorcontrib>Lavé, Thierry</creatorcontrib><creatorcontrib>Rowland, Malcolm</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, Dennis A.</au><au>van Waterschoot, Robert A.B.</au><au>Parrott, Neil J.</au><au>Olivares-Morales, Andrés</au><au>Lavé, Thierry</au><au>Rowland, Malcolm</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Importance of target-mediated drug disposition for small molecules</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2018-12</date><risdate>2018</risdate><volume>23</volume><issue>12</issue><spage>2023</spage><epage>2030</epage><pages>2023-2030</pages><issn>1359-6446</issn><eissn>1878-5832</eissn><abstract>•Target-mediated drug disposition for small molecules is not addressed systematically.•TMDD has a major influence on drug distribution and clearance.•TMDD results in unpredictable and non-linear pharmacokinetics.•TMDD confounds human microdosing approaches. Target concentration is typically not considered in drug discovery. However, if targets are expressed at relatively high concentrations and compounds have high affinity, such that most of the drug is bound to its target, in vitro screens can give unreliable information on compound affinity. In vivo, a similar situation will generate pharmacokinetic (PK) profiles that deviate greatly from those normally expected, owing to target binding affecting drug distribution and clearance. Such target-mediated drug disposition (TMDD) effects on small molecules have received little attention and might only become apparent during clinical trials, with the potential for data misinterpretation. TMDD also confounds human microdosing approaches by providing therapeutically unrepresentative PK profiles. Being aware of these phenomena will improve the likelihood of successful drug discovery and development.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29928850</pmid><doi>10.1016/j.drudis.2018.06.010</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-9959-0810</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1359-6446
ispartof Drug discovery today, 2018-12, Vol.23 (12), p.2023-2030
issn 1359-6446
1878-5832
language eng
recordid cdi_proquest_miscellaneous_2058499901
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Clinical Trials as Topic
Drug Delivery Systems - methods
Humans
Small Molecule Libraries - pharmacokinetics
Tissue Distribution - physiology
title Importance of target-mediated drug disposition for small molecules
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T08%3A50%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Importance%20of%20target-mediated%20drug%20disposition%20for%20small%20molecules&rft.jtitle=Drug%20discovery%20today&rft.au=Smith,%20Dennis%20A.&rft.date=2018-12&rft.volume=23&rft.issue=12&rft.spage=2023&rft.epage=2030&rft.pages=2023-2030&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/j.drudis.2018.06.010&rft_dat=%3Cproquest_cross%3E2058499901%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2058499901&rft_id=info:pmid/29928850&rft_els_id=S1359644618300837&rfr_iscdi=true